Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 6/2014

01-06-2014 | Gynecological Cancers (N Reed, Section Editor)

Mucinous Tumors of the Ovary: Current Thoughts on Diagnosis and Management

Authors: Jubilee Brown, Michael Frumovitz

Published in: Current Oncology Reports | Issue 6/2014

Login to get access

Abstract

Mucinous tumors of the ovary represent a spectrum of neoplastic disorders, including benign mucinous cystadenoma, pseudomyxoma peritonei, mucinous tumors of low malignant potential (borderline), and invasive mucinous ovarian carcinoma. These tumors are related closely to each other and are distinct from other histologic subtypes of epithelial ovarian neoplasms from a clinical, histologic, and molecular standpoint. A continuum appears to be present from benign to borderline to malignant, which is different from other types of epithelial ovarian cancer. Mutational profiles are also distinct, as KRAS mutations are common, but p53 and BRCA mutations are infrequent. These characteristics lead to specific biologic behavior and guide both clinical management and research efforts in patients with mucinous ovarian tumors.
Literature
1.
Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010;117:491–6.PubMedCrossRef
2.
Hess V, A’Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040–4.PubMedCrossRef
3.
Mondal SK, Banyopadhyay R, Nag DR, et al. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: a 10-year study in a tertiary hospital in eastern India. J Cancer Res Ther. 2011;4:433–7.CrossRef
4.
Koonings PP. Relative frequencies of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74:921–6.PubMed
5.
Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529–41.PubMedCrossRef
6.
Chiesa AG, Deavers MT, Veras E, et al. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol. 2010;29:108–12.PubMedCrossRef
7.
8.
Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinoma in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985–93.PubMedCrossRef
9.
Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113:331–4.PubMedCrossRef
10.
McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.PubMedCrossRef
11.
Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophos- phamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708.PubMedCrossRef
12.
Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18:106–15.PubMed
13.
Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419–25.PubMedCentralPubMedCrossRef
14.
Hart WR, Norris HJ. Borderline and malignant mucinous tumours of the ovary: histologic criteria and clinical behavior. Cancer. 1973;31:1031–45.PubMedCrossRef
15.
Lack EE, Young RH, Scully RE. Pathology of ovarian neoplasms in childhood and adolescence. Pathol Annu. 1992;27:281–356.PubMed
16.
Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999;23:617–35.PubMedCrossRef
17.
Tait DL, Miller DS. Multicystic ovarian tumor weighing 156 lbs: the second largest tumor in Texas. Tex Med. 1997;93:89.PubMed
18.
Chao A, Chao A, Yen YS, Huang CH. Abdominal compartment syndrome secondary to ovarian mucinous cystadenoma. Obstet Gynecol. 2004;104:1180–2.PubMedCrossRef
19.
Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281–92.PubMedCrossRef
20.
Boger-Megiddo I, Weiss NS. Histologic subtypes and laterality of primary epithelial ovarian tumors. Gynecol Oncol. 2005;97:80–3.PubMedCrossRef
21.
Khunamornpong S, Suprasert P, Pojchamarnwiputh S, et al. Primary and metastatic mucinous adenocarcinomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol. 2006;101:152–7.PubMedCrossRef
22.
Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41–4.PubMedCrossRef
23.
Cho YH, Kim DY, Kim JH, et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol. 2006;103:878–82.PubMedCrossRef
24.
Roger N, Zafrani Y, Uzan C, et al. Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer? Ann Surg Oncol. 2008;15:333–8.PubMedCrossRef
25.
Schmeler KM, Tao X, Frumovitz M, et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010;116:269–73.PubMedCentralPubMedCrossRef
26.
Leblanc E, Querleu D, Narducci F, et al. Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol. 2004;94:624–9.PubMedCrossRef
27.
Tholander B, Taube A, Lindgren A, et al. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol. 1990;39:26–33.PubMedCrossRef
28.
Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215–45.PubMedCrossRef
29.
30.
Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008;108:276–81.PubMedCrossRef
31.
Fleming GF, Ronnett BM, Seidman J, et al. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, editors. Principles and practice of gynecologic oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 763–835.
32.
NCCN Guidelines - Ovarian Cancer, Version 2.2013, accessed on 10/1/2013.
33.
Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87:1–7.PubMedCrossRef
34.
Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115:4118–26.PubMedCrossRef
35.
36.
Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‘Pseudomyxoma Peritonei’. Am J Surg Pathol. 2000;24:1447–64.PubMedCrossRef
37.
Lin JE, Seo S, Kushner DM, Rose SL. The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol. 2013;208:46e1–4.
38.
Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.PubMedCrossRef
39.
40.
41.
Leys CM, Gasior AC, Hornberger LH, St. Peter SD. Laparoscopic resection of massive ovarian mucinous cystadenoma. J Laparoendosc Adv Surg Tech. 2012;22:307–10.CrossRef
42.
Eltabbakh GH, Charbonneau AM, Eltabbakh NG. Laparoscopic surgery for large benign ovarian cysts. Gynecol Oncol. 2008;108:72–6.PubMedCrossRef
43.
Ji J, Forsti A, Sundquist J, Lenner P, Hemminki K. Survival in ovarian cancer patients by histology and family history. Acta Oncol. 2008;47:1133–9.PubMedCrossRef
44.
Winter III WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621–7.PubMedCrossRef
45.
Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005;97:436–41.PubMedCrossRef
46.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008;8:252.PubMedCentralPubMedCrossRef
47.
Rodriguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26:139–52.PubMedCrossRef
48.
Ronnett BM, Yemelyanova AV, Vang R, et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol. 2008;32:1835–53.PubMedCrossRef
49.
Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol. 2005;24:67–72.PubMedCrossRef
50.
51.
Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–9.PubMed
52.
Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003;90:378–81.PubMedCrossRef
53.
Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 1993;53:1489–92.PubMed
54.
Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Fam Cancer. 2007;6:491–7.PubMedCrossRef
55.
Evans DG, Young K, Bulman M, et al. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clin Genet. 2008;73:338–45.PubMedCrossRef
56.
57.
Marchini S, Mariani P, Chiorino G, et al. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res. 2008;14:7850–60.PubMedCrossRef
58.
Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer. 2006;94:904–13.PubMedCentralPubMedCrossRef
59.
Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol. 2006;37:1042–9.PubMedCrossRef
60.
Brun JL, Cortez A, Commo F, Uzan S, Rouzier R, Darai E. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol. 2008;33:1239–46.PubMed
61.
62.
63.
Sato S, Itamochi H, Kigawa J, et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009;100:546–51.PubMedCrossRef
Metadata
Title
Mucinous Tumors of the Ovary: Current Thoughts on Diagnosis and Management
Authors
Jubilee Brown
Michael Frumovitz
Publication date
01-06-2014
Publisher
Springer US
Published in
Current Oncology Reports / Issue 6/2014
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-014-0389-x
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits